Therapeutic response of patients with adult Still's disease to biologic agents: multicenter results in Japan

被引:53
作者
Suematsu, Rie [1 ]
Ohta, Akihide [2 ]
Matsuura, Emi [3 ]
Takahashi, Hiroki [4 ]
Fujii, Takao [5 ]
Horiuchi, Takahiko [6 ]
Minota, Seiji [7 ]
Ishigatsubo, Yoshiaki [8 ]
Ota, Toshiyuki [9 ]
Takei, Shuji [10 ]
Soejima, Sachiko [1 ]
Inoue, Hisako [1 ]
Koarada, Syuichi [1 ]
Tada, Yoshifumi [1 ]
Nagasawa, Kohei [1 ]
机构
[1] Saga Univ, Sch Med, Dept Internal Med, Div Rheumatol, Saga 8498501, Japan
[2] Saga Univ, Sch Med, Dept Adult & Gerontol Nursing, Saga 8498501, Japan
[3] Kwassui Womens Univ, Fac Nursing, Nagasaki, Japan
[4] Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido, Japan
[5] Kyoto Univ, Grad Sch Med, Dept Rheumatol & Clin Immunol, Kyoto, Japan
[6] Kyushu Univ, Grad Sch Med Sci, Dept Med & Biosyst Sci, Fukuoka 812, Japan
[7] Jichi Med Univ, Dept Internal Med, Div Rheumatol Clin Immunol, Shimotsuke, Tochigi, Japan
[8] Yokohama City Univ, Grad Sch Med, Dept Internal Med & Clin Immunol, Yokohama, Kanagawa, Japan
[9] Univ Occupat & Environm Hlth, Dept Lab & Transfus Med, Kitakyushu, Fukuoka 807, Japan
[10] Kagoshima Univ, Fac Med, Sch Hlth Sci, Kagoshima 890, Japan
关键词
Adult Still's disease; Multicenter study; Biologic agents; Tocilizumab; TUMOR-NECROSIS-FACTOR; CYTOKINE PROFILES; FACTOR-ALPHA; ETANERCEPT; TOCILIZUMAB; MANAGEMENT; INFLIXIMAB; EFFICACY; ANAKINRA;
D O I
10.1007/s10165-011-0569-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The efficacy of biologics in treating adult Still's disease (ASD) is suggested, but the information is still lacking and the validation is insufficient. To determine the efficacy of several biologic agents in refractory ASD in Japan, a multicenter survey was performed. Clinical data on 16 ASD patients who had been treated with at least 1 of the biological agents (total 24 occasions) were collected retrospectively. Infliximab was used in 9 cases, etanercept in 4, and tocilizumab in 11. Half of the patients that had been treated initially with infliximab or etanercept were changed to another biologics. Tocilizumab was effective in cases switched from another 2 drugs. Tocilizumab showed efficacy in treating both systemic and arthritic symptoms and showed apparent steroid-sparing effect and the highest continuation rate. Tocilizumab may be a promising biologic agent in refractory ASD.
引用
收藏
页码:712 / 719
页数:8
相关论文
共 34 条
[1]   Reactive haemophagocytic syndrome in adult-onset Still's disease: a report of six patients and a review of the literature [J].
Arlet, J.-B. ;
Huong, D. Le Thi ;
Marinho, A. ;
Amoura, Z. ;
Wechsler, B. ;
Papo, T. ;
Piette, J-C .
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (12) :1596-1601
[2]  
Cavagna L, 2001, CLIN EXP RHEUMATOL, V19, P329
[3]  
Chen DY, 2004, J RHEUMATOL, V31, P2189
[4]  
Choi JH, 2003, J RHEUMATOL, V30, P2422
[5]   Tocilizumab for multirefractory adult-onset Still's disease [J].
De Bandt, M. ;
Saint-Marcoux, B. .
ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (01) :153-154
[6]   Diagnosis and management of adult onset Still's disease [J].
Efthimiou, P ;
Paik, PK ;
Bielory, L .
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (05) :564-572
[7]   Pathogenesis and management of adult-onset Still's disease [J].
Efthimiou, Petros ;
Georgy, Sharon .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2006, 36 (03) :144-152
[8]   Tumour necrosis factor a blocking agents in refractory adult Still's disease: an observational study of 20 cases [J].
Fautrel, B ;
Sibilia, J ;
Mariette, X ;
Combe, B .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (02) :262-266
[9]   Rapid responses to anakinra in patients with refractory adult-onset Still's disease [J].
Fitzgerald, AA ;
LeClercq, SA ;
Yan, A ;
Homik, JE ;
Dinarello, CA .
ARTHRITIS AND RHEUMATISM, 2005, 52 (06) :1794-1803
[10]   Efficacy of Traditional and Biologic Agents in Different Clinical Phenotypes of Adult-Onset Still's Disease [J].
Franchini, Stefano ;
Dagna, Lorenzo ;
Salvo, Fulvio ;
Aiello, Patrizia ;
Baldissera, Elena ;
Sabbadini, Maria Grazia .
ARTHRITIS AND RHEUMATISM, 2010, 62 (08) :2530-2535